These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 28812060)
1. Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. Jaime-Ramirez AC; Yu JG; Caserta E; Yoo JY; Zhang J; Lee TJ; Hofmeister C; Lee JH; Kumar B; Pan Q; Kumar P; Baiocchi R; Teknos T; Pichiorri F; Kaur B; Old M Mol Ther Oncolytics; 2017 Jun; 5():87-96. PubMed ID: 28812060 [TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. Stiff A; Caserta E; Sborov DW; Nuovo GJ; Mo X; Schlotter SY; Canella A; Smith E; Badway J; Old M; Jaime-Ramirez AC; Yan P; Benson DM; Byrd JC; Baiocchi R; Kaur B; Hofmeister CC; Pichiorri F Mol Cancer Ther; 2016 May; 15(5):830-41. PubMed ID: 26809490 [TBL] [Abstract][Full Text] [Related]
3. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Kelly KR; Espitia CM; Zhao W; Wendlandt E; Tricot G; Zhan F; Carew JS; Nawrocki ST Oncotarget; 2015 Dec; 6(38):41275-89. PubMed ID: 26513296 [TBL] [Abstract][Full Text] [Related]
4. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Sborov DW; Nuovo GJ; Stiff A; Mace T; Lesinski GB; Benson DM; Efebera YA; Rosko AE; Pichiorri F; Grever MR; Hofmeister CC Clin Cancer Res; 2014 Dec; 20(23):5946-55. PubMed ID: 25294913 [TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331 [TBL] [Abstract][Full Text] [Related]
6. Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy. Islam S; Espitia CM; Persky DO; Carew JS; Nawrocki ST Blood Adv; 2020 Oct; 4(20):5297-5310. PubMed ID: 33108458 [TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo. Dincman TA; Beare JE; Ohri SS; Gallo V; Hetman M; Whittemore SR Int J Dev Neurosci; 2016 Nov; 54():53-61. PubMed ID: 27587342 [TBL] [Abstract][Full Text] [Related]
11. Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Datta J; Islam M; Dutta S; Roy S; Pan Q; Teknos TN Oral Oncol; 2016 May; 56():32-9. PubMed ID: 27086484 [TBL] [Abstract][Full Text] [Related]
14. PX-12 synergistically enhances the therapeutic efficacy of vorinostat under hypoxic tumor microenvironment in oral squamous cell carcinoma in vitro. Akhlaq R; Khan T; Ahmed T; Musharraf SG; Ali A Drug Dev Res; 2023 May; 84(3):556-560. PubMed ID: 36808757 [TBL] [Abstract][Full Text] [Related]
15. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor. Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460 [TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Gillenwater AM; Zhong M; Lotan R Mol Cancer Ther; 2007 Nov; 6(11):2967-75. PubMed ID: 18025281 [TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. Erlich RB; Kherrouche Z; Rickwood D; Endo-Munoz L; Cameron S; Dahler A; Hazar-Rethinam M; de Long LM; Wooley K; Guminski A; Saunders NA Br J Cancer; 2012 Jan; 106(1):107-15. PubMed ID: 22116303 [TBL] [Abstract][Full Text] [Related]
19. Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Smith KT; Martin-Brown SA; Florens L; Washburn MP; Workman JL Chem Biol; 2010 Jan; 17(1):65-74. PubMed ID: 20142042 [TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus. Harryvan TJ; Golo M; Dam N; Schoonderwoerd MJA; Farshadi EA; Hornsveld M; Hoeben RC; Hawinkels LJAC; Kemp V Cancer Gene Ther; 2022 Dec; 29(12):1918-1929. PubMed ID: 35869278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]